A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer

被引：0
|
作者：
Church, David N. [1 ]
Price, Chris G. A. [2 ]
机构：
[1] Univ Oxford, John Racliffe Hosp, Weatherall Inst Mol Med, Headley Way, Oxford OX3 9DS, England
[2] Bristol Haematol & Oncol Ctr, Bristol BS1 8ED, Avon, England
来源：
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2009年 / 1卷
关键词：
breast cancer; trastuzumab; metastatic; ERBB2; HER2;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The ERBB2 or HER2 receptor is overexpressed in 25% of breast cancers and is associated with poor prognosis. Trastuzumab, a monoclonal antibody targeting HER2 has been demonstrated to improve survival when combined with chemotherapy for the treatment of HER2 overexpressing metastatic breast cancer (MBC). Further studies have endeavoured to clarify the optimum chemotherapy regimen in combination with trastuzumab for MBC and its use together with novel biological agents. This review summarises these data together with preclinical studies exploring the mechanism of trastuzumab action and causes of drug resistance. The frequent incidence of brain metastases in patients on trastuzumab is highlighted, and data on the continuation of trastuzumab following CNS and non-CNS progression reviewed.
引用
收藏
页码：557 / 570
页数：14
相关论文
共 50 条
  • [21] Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer
    Gullo, Giuseppe
    Bettio, Daniela
    Torri, Valter
    Masci, Giovanna
    Salvini, Piermario
    Santoro, Armando
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (02) : 179 - 183
  • [22] Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
    Anthony F. Yu
    Roy B. Mukku
    Shivani Verma
    Jennifer E. Liu
    Kevin C. Oeffinger
    Richard M. Steingart
    Clifford A. Hudis
    Chau T. Dang
    Breast Cancer Research and Treatment, 2017, 166 : 241 - 247
  • [23] Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
    Yu, Anthony F.
    Mukku, Roy B.
    Verma, Shivani
    Liu, Jennifer E.
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 241 - 247
  • [24] Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
    Costa, R. B.
    Kurra, G.
    Greenberg, L.
    Geyer, C. E.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2153 - 2160
  • [25] HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review
    Chen, Min-long
    Yu, Wenjie
    Cui, Binbin
    Yu, Yijian
    Ma, Zhaosheng
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [26] Markers of inflammation as predictors of efficacy of trastuzumab therapy in HER2-positive metastatic breast cancer patients
    Vynnychenko, O.
    Moskalenko, Y.
    Moskalenko, R.
    REGULATORY MECHANISMS IN BIOSYSTEMS, 2025, 16 (01)
  • [27] MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients
    Lote, Hazel
    Mousoullou, Florentia
    Vlachogiannis, George
    Lampis, Andrea
    Satchwell, Laura
    Peckitt, Clare
    Fong, Caroline
    Begum, Ruwaida
    Kidd, Shannon
    Cromarty, Susan
    Gordon, Anderley
    Fribbens, Charlotte
    Rao, Sheela
    Starling, Naureen
    Chau, Ian
    Cunningham, David
    Valeri, Nicola
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [28] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [29] Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy
    Rossi, Valentina
    Nole, Franco
    Redana, Stefania
    Adamoli, Laura
    Martinello, Rossella
    Aurilio, Gaetano
    Verri, Elena
    Sapino, Anna
    Viale, Giuseppe
    Aglietta, Massimo
    Montemurro, Filippo
    BREAST, 2014, 23 (01) : 44 - 49
  • [30] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer
    Andrew D. Seidman
    Larry Norton
    Current Oncology Reports, 2005, 7 (1) : 9 - 11
12345